Question 1

What is AnBogen Therapeutics?

Accepted Answer

AnBogen Therapeutics is a Entity.

Question 2

How often does AnBogen Therapeutics appear in global news?

Accepted Answer

Tracked across 5 news events drawn from 50 articles.

Question 3

When was AnBogen Therapeutics first tracked by NewsDesk?

Accepted Answer

First tracked on Jan 17, 2026.

Question 4

When was AnBogen Therapeutics last mentioned in news?

Accepted Answer

Last active on Jun 08, 2026.

Question 5

What is AnBogen Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 43 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AnBogen Therapeutics in global news coverage?

Accepted Answer

Attention score of 8, derived from article volume and coverage intensity across 5 events.

Question 7

What is the most recent event involving AnBogen Therapeutics?

Accepted Answer

AnBogen Imofinostat Cancer Breakthroughs (Apr 13, 2026, 6 articles).

Question 8

How did the "AnBogen Imofinostat Cancer Breakthroughs" event impact AnBogen Therapeutics?

Accepted Answer

AnBogen Therapeutics announced two key research abstracts for its lead compound, Imofinostat (ABT-301), demonstrating its potential in enhancing immunotherapy for colorectal cancer and overcoming chemotherapy resistance in pancreatic cancer. The company is also advancing a Phase 1/2 clinical trial and plans for an Emerging Stock Market listing.

Question 9

How did the "Protagenic Therapeutics Engages Regulatory, Operations Advisors" event impact AnBogen Therapeutics?

Accepted Answer

AnBogen Therapeutics engaged two consulting firms to advance its lead candidate, PT-00114, into Phase 2 clinical studies, which is expected to strengthen its operational processes and regulatory strategy.

Question 10

How did the "Protagonist Therapeutics CEO Attends Conferences" event impact AnBogen Therapeutics?

Accepted Answer

AnBogen Therapeutics will participate in two investment bank conferences, providing an opportunity to present its pipeline and potentially attract investor interest.

Question 11

How did the "ASCO 2026 Oncology Data Presentations" event impact AnBogen Therapeutics?

Accepted Answer

AnBogen Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced new data related to elacestrant and tagraxofusp at the 2026 ASCO Annual Meeting, and its partner Karyopharm Therapeutics presented data on selinexor.

Question 12

How is this data collected?

Accepted Answer

NewsDesk aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.